Literature DB >> 24012878

HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.

Ryusho Kariya1, Manabu Taura, Shinya Suzu, Hirofumi Kai, Harutaka Katano, Seiji Okada.   

Abstract

Primary effusion lymphoma (PEL) is a non-Hodgkin lymphoma that occurs predominantly in patients with advanced AIDS. In this study, we examined the effect of HIV protease inhibitors, Lopinavir (LPV), Ritonavir (RTV) and Darunavir (DRV) on PEL cell lines in vitro and in vivo. LPV and RTV, but not DRV induced caspase-dependent apoptosis and suppressed NF-κB activity by inhibiting IKK phosphorylation in PEL cells. In a PEL xenograft mouse model, LPV significantly inhibited the growth and invasion of PEL cells. These results suggest that LPV may have promise for the treatment and prevention of PEL, which occurs in HIV/AIDS patients.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  HIV-1 protease inhibiton; IκB kinase; NF-κB; Primary effusion lymphoma

Mesh:

Substances:

Year:  2013        PMID: 24012878     DOI: 10.1016/j.canlet.2013.08.045

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination.

Authors:  Indhira De La Rosa; Iona M Munjal; Maria Rodriguez-Barradas; Xiaoying Yu; Liise-Anne Pirofski; Daniel Mendoza
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

Review 2.  HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape.

Authors:  Virginia Carroll; Alfredo Garzino-Demo
Journal:  Pathog Dis       Date:  2015-06-29       Impact factor: 3.166

Review 3.  Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities.

Authors:  Lilian Makgoo; Salerwe Mosebi; Zukile Mbita
Journal:  Front Mol Biosci       Date:  2022-05-10

4.  Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo.

Authors:  Svetlana Paskas; Emanuela Mazzon; Maria Sofia Basile; Eugenio Cavalli; Yousef Al-Abed; Mingzhu He; Sara Rakocevic; Ferdinando Nicoletti; Sanja Mijatovic; Danijela Maksimovic-Ivanic
Journal:  Invest New Drugs       Date:  2019-02-01       Impact factor: 3.850

5.  Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

Authors:  Huixin Yu; Jeroen J M A Hendrikx; Sven Rottenberg; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

6.  Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Christopher S Bryant; Aamer M Qazi; Sanjeev Kumar; Sreedhar Chamala; Shu T Kung; Ramana S Sanka; Udaya S Puttagunta; Donald W Weaver; Scott A Gruber
Journal:  Pharmaceuticals (Basel)       Date:  2014-01-09

Review 7.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

Review 8.  The Effect of COVID-19 on NF-κB and Neurological Manifestations of Disease.

Authors:  Don A Davies; Aida Adlimoghaddam; Benedict C Albensi
Journal:  Mol Neurobiol       Date:  2021-06-01       Impact factor: 5.590

9.  Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents.

Authors:  Manoj Kumar Mahto; Nanda Kumar Yellapu; Ravendra Babu Kilaru; Naga Raju Chamarthi; Matcha Bhaskar
Journal:  Bioinformation       Date:  2014-04-23

Review 10.  The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.

Authors:  Akinori Sato
Journal:  Onco Targets Ther       Date:  2015-04-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.